Quantitative Analysis of Complex DrugeDrug Interactions Between Repaglinide and Cyclosporin A/Gemfibrozil Using Physiologically Based Pharmacokinetic Models With In Vitro Transporter/Enzyme Inhibition Data

被引:15
作者
Kim, Soo-Jin [1 ,2 ]
Toshimoto, Kota [1 ]
Yao, Yoshiaki [3 ]
Yoshikado, Takashi [1 ]
Sugiyama, Yuichi [1 ]
机构
[1] RIKEN, RIKEN Cluster Ind Partnerships, RIKEN Innovat Ctr, Sugiyama Lab, Yokohama, Kanagawa, Japan
[2] CJ HealthCare, R&D Ctr, Drug Evaluat Grp, Icheon, South Korea
[3] Astellas Pharma Inc, Drug Discovery Res, Anal & Pharmacokinet Res Labs, Ibaraki, Japan
基金
日本学术振兴会;
关键词
clinical trial simulations; drug interactions; pharmacokinetics; physiologically based pharmacokinetic modeling; organic anion-transporting polypeptide transporters; CYP enzymes; DRUG-DRUG INTERACTIONS; PLASMA-CONCENTRATIONS; TISSUE DISTRIBUTION; HEPATIC-UPTAKE; GEMFIBROZIL; CYP2C8; PREDICTION; INCREASES; MECHANISM; CYP3A4;
D O I
10.1016/j.xphs.2017.04.063
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Quantitative analysis of transporter-and enzyme-mediated complex drugedrug interactions (DDIs) is challenging. Repaglinide (RPG) is transported into the liver by OATP1B1 and then is metabolized by CYP2C8 and CYP3A4. The purpose of this study was to describe the complex DDIs of RPG quantitatively based on unified physiologically based pharmacokinetic (PBPK) models using in vitro K-i values for OATP1B1, CYP3A4, and CYP2C8. Cyclosporin A (CsA) or gemfibrozil (GEM) increased the blood concentrations of RPG. The time profiles of RPG and the inhibitors were analyzed by PBPK models, considering the inhibition of OATP1B1 and CYP3A4 by CsA or OATP1B1 inhibition by GEM and its glucuronide and the mechanism-based inhibition of CYP2C8 by GEM glucuronide. RPG-CsA interaction was closely predicted using a reported in vitro Ki, OATP1B1 value in the presence of CsA preincubation. RPG-GEM interaction was underestimated compared with observed data, but the simulation was improved with the increase of f(m,CYP2C8). These results based on in vitro Ki values for transport and metabolism suggest the possibility of a bottom-up approach with in vitro inhibition data for the prediction of complex DDIs using unified PBPK models and in vitro fm value of a substrate for multiple enzymes should be considered carefully for the prediction. (C) 2017 American Pharmacists Association (R). Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:2715 / 2726
页数:12
相关论文
共 43 条
  • [1] [Anonymous], Guideline on the investigation of drug interactions
  • [2] [Anonymous], DRUG INT GUID DRUG D
  • [3] CLUSTER NEWTON METHOD FOR SAMPLING MULTIPLE SOLUTIONS OF UNDERDETERMINED INVERSE PROBLEMS: APPLICATION TO A PARAMETER IDENTIFICATION PROBLEM IN PHARMACOKINETICS
    Aoki, Yasunori
    Hayami, Ken
    De Sterck, Hans
    Konagaya, Akihiko
    [J]. SIAM JOURNAL ON SCIENTIFIC COMPUTING, 2014, 36 (01) : B14 - B44
  • [4] CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide
    Bidstrup, TB
    Bjornsdottir, I
    Sidelmann, UG
    Thomsen, MS
    Hansen, KT
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 (03) : 305 - 314
  • [5] European Medicines Agency, GUID QUAL REP PHYS B
  • [6] Selection of Alternative CYP3A4 Probe Substrates for Clinical Drug Interaction Studies Using In Vitro Data and In Vivo Simulation
    Foti, Robert S.
    Rock, Dan A.
    Wienkers, Larry C.
    Wahlstrom, Jan L.
    [J]. DRUG METABOLISM AND DISPOSITION, 2010, 38 (06) : 981 - 987
  • [7] Fujino Hideki, 2003, Drug Metabol Drug Interact, V19, P161
  • [8] Membrane transporters in drug development
    Giacomini, Kathleen M.
    Huang, Shiew-Mei
    Tweedie, Donald J.
    Benet, Leslie Z.
    Brouwer, Kim L. R.
    Chu, Xiaoyan
    Dahlin, Amber
    Evers, Raymond
    Fischer, Volker
    Hillgren, Kathleen M.
    Hoffmaster, Keith A.
    Ishikawa, Toshihisa
    Keppler, Dietrich
    Kim, Richard B.
    Lee, Caroline A.
    Niemi, Mikko
    Polli, Joseph W.
    Sugiyama, Yuicchi
    Swaan, Peter W.
    Ware, Joseph A.
    Wright, Stephen H.
    Yee, Sook Wah
    Zamek-Gliszczynski, Maciej J.
    Zhang, Lei
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (03) : 215 - 236
  • [9] Analysis of nonlinear and nonsteady state hepatic extraction with the dispersion model using the finite difference method
    Hisaka, A
    Sugiyama, Y
    [J]. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1998, 26 (05): : 495 - 519
  • [10] Gemfibrozil Is a Strong Inactivator of CYP2C8 in Very Small Multiple Doses
    Honkalammi, J.
    Niemi, M.
    Neuvonen, P. J.
    Backman, J. T.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 (05) : 846 - 855